Amivantamab (Rybrevant)
Targeted TherapyApproved for: NSCLCBiomarker: EGFR exon 20 The FDA has approved amivantamab-vmjw (Rybrevant) as the first treatment for adult patients with non–small cell lung cancer (NSCLC) who harbor EGFR exon 20 insertion mutations. Related Research News FDA Approves Repotrectinib...